Across TCGA pan-cancer cohorts, FDPSP6 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of FDPSP6’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where FDPSP6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FDPSP6 is over-expressed in tumor.
LIHC are the cancer types where FDPSP6 tumor–normal differential expression is most reproducible.